company background image
BMY

Bristol-Myers Squibb NYSE:BMY Stock Report

Last Price

US$49.02

Market Cap

US$101.2b

7D

0.2%

1Y

-38.1%

Updated

27 Nov, 2023

Data

Company Financials +

Bristol-Myers Squibb Company

NYSE:BMY Stock Report

Mkt Cap: US$101.2b

BMY Stock Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

BMY fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance5/6
Financial Health3/6
Dividends5/6

Bristol-Myers Squibb Company Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bristol-Myers Squibb
Historical stock prices
Current Share PriceUS$49.02
52 Week HighUS$81.44
52 Week LowUS$48.42
Beta0.37
1 Month Change-3.92%
3 Month Change-22.00%
1 Year Change-38.06%
3 Year Change-21.44%
5 Year Change-8.00%
Change since IPO244.00%

Recent News & Updates

Bristol-Myers Squibb: The Patent Expiry Challenge

Nov 23

Bristol Myers Squibb: Bright Future Ahead

Nov 17

Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet

Nov 08
Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet

Recent updates

Bristol-Myers Squibb: The Patent Expiry Challenge

Nov 23

Bristol Myers Squibb: Bright Future Ahead

Nov 17

Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet

Nov 08
Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet

Bristol-Myers Squibb: Time To Get Greedy

Oct 21

Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud

Oct 09

Bristol Myers Squibb: Close To Fair Value, Headwinds For Next Few Years

Sep 26

Bristol Myers Squibb: Pharma And Government Playing 'Chicken' Over New Drug Pricing Rules

Sep 16

Here's Why We Think Bristol-Myers Squibb (NYSE:BMY) Might Deserve Your Attention Today

Sep 09
Here's Why We Think Bristol-Myers Squibb (NYSE:BMY) Might Deserve Your Attention Today

Bristol-Myers Squibb: Patents, Profits, And Prognosis

Aug 24

Here's Why Bristol-Myers Squibb (NYSE:BMY) Can Manage Its Debt Responsibly

Aug 01
Here's Why Bristol-Myers Squibb (NYSE:BMY) Can Manage Its Debt Responsibly

Bristol-Myers: Potentially Set To Soar And Too Cheap To Ignore

Jul 19

Bristol-Myers Squibb: Back In The Doldrums - Or Just Pausing For Breath?

Jul 06

Bristol Myers Squibb: Take The Red Pill

Jun 05

High Quality Dividend Growth Near 52-Week Lows: Bristol-Myers Squibb Is A Good Bet

May 30

Here's Why We Think Bristol-Myers Squibb (NYSE:BMY) Might Deserve Your Attention Today

May 21
Here's Why We Think Bristol-Myers Squibb (NYSE:BMY) Might Deserve Your Attention Today

Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet

Apr 27
Bristol-Myers Squibb (NYSE:BMY) Has A Pretty Healthy Balance Sheet

Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.57

Apr 05
Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.57

Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.57

Mar 09
Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.57

Bristol's Opdivo improves disease-free survival in urothelial carcinoma over long term

Feb 17

Shareholder Returns

BMYUS PharmaceuticalsUS Market
7D0.2%-0.1%0.1%
1Y-38.1%-3.1%13.5%

Return vs Industry: BMY underperformed the US Pharmaceuticals industry which returned -3.1% over the past year.

Return vs Market: BMY underperformed the US Market which returned 13.5% over the past year.

Price Volatility

Is BMY's price volatile compared to industry and market?
BMY volatility
BMY Average Weekly Movement3.3%
Pharmaceuticals Industry Average Movement10.4%
Market Average Movement6.0%
10% most volatile stocks in US Market15.4%
10% least volatile stocks in US Market2.9%

Stable Share Price: BMY is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: BMY's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
188734,300Chris Boernerhttps://www.bms.com

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Bristol-Myers Squibb Company Fundamentals Summary

How do Bristol-Myers Squibb's earnings and revenue compare to its market cap?
BMY fundamental statistics
Market CapUS$101.25b
Earnings (TTM)US$8.29b
Revenue (TTM)US$44.94b

12.0x

P/E Ratio

2.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BMY income statement (TTM)
RevenueUS$44.94b
Cost of RevenueUS$10.33b
Gross ProfitUS$34.60b
Other ExpensesUS$26.32b
EarningsUS$8.29b

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Feb 02, 2024

Earnings per share (EPS)4.07
Gross Margin77.01%
Net Profit Margin18.44%
Debt/Equity Ratio129.6%

How did BMY perform over the long term?

See historical performance and comparison

Dividends

4.7%

Current Dividend Yield

58%

Payout Ratio